-
Congratulations! Dr. Jian Zhou has been elected as the President-elect of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE)
From July 6th to 8th, 2023, the 13th annual meeting of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE) was held in Seoul, South Korea, with the participation of nearly 1000 experts and scholars in the field of liver cancer from around the world. The current President and internationally renowned hepatopancreatobiliary surgeon, Dr. Norihiro Kokudo,…
-
Dr. Zhaochong Zeng: Enhancing Efficiency and Reducing Burden – Latest Advances in Radiotherapy for Liver Cancer Treatment
Stereotactic Body Radiotherapy (SBRT), as a novel radiotherapy technique, has achieved encouraging results in the treatment of liver cancer. It not only improves local tumor control but also reduces distant metastases caused by tumors. Additionally, it minimizes radiation therapy-related complications, enhancing the quality of life for patients after treatment. However, how to maximize the role…
-
Dr. Ming Zhao: Key Clinical Research in Hepatocellular Carcinoma
From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) was held in Seoul, South Korea. Hepatocellular carcinoma (HCC) experts from around the world gathered to rekindle academic discussions on HCC’s basics, clinical aspects, research, and technology offline. The conference featured the latest research results from over a thousand…
-
Dr. Huichuan Sun: Focusing on the Asia-Pacific Region, Leading the Frontier – Exploring Breakthroughs in the Treatment of Hepatobiliary Tumor
The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) recently concluded in Seoul, South Korea, bringing together top experts in liver and biliary system tumors from around the world to discuss clinical hot topics and challenges. Dr. Huichuan Sun from Zhongshan Hospital, Fudan University, China, shares and interprets the latest developments and frontiers, including…
-
Voice of China | Professor Jidong Jia and Professor Hong You’s Team: Carvedilol Combined with Antiviral Treatment Can Delay the Progression of Moderat
Editor’s Note: Portal hypertension is the main pathophysiological cause of decompensation events in patients with cirrhosis and is a major driver of liver function deterioration. Non-selective β-blockers (NSBBs) are widely…
-
AASLD Voice of China| Dr. Xianbo Wang’s Team: Multiple Studies in the Field of Primary Biliary Cholangitis Presented at AASLD Meeting
Editor’s Note: The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) was held in Boston, USA, from November 10 to 14, 2023. Dr. Xianbo Wang’s…
-
Dr. Xinwei Wang: The Molecular Landscape and Clinical Significance of Liver Cancer
Liver cancer is one of the most prevalent and deadliest cancers in China. Due to the low early diagnosis rate of liver cancer in clinical practice, treatment options such as radical liver resection and transplantation face significant limitations. In recent years, there has been a surge in liver cancer genomics research, providing new insights into…
-
Interview with Dr. Girard Deciphers at ELCC 2023
The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the…
Connecting Medical Expertise through Media